3-Chloro-5-methylbenzyl amine | 1240305-91-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Chloro-5-methylbenzyl amine
• 英文别名: (3-chloro-5-methylphenyl)methanamine
• CAS: 1240305-91-2
• 化学式: C₈H₁₀ClN
• 分子量: 155.62
• InChiKey: YIUQWUGXTNVAOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• APPLICATIONS THÉRAPEUTIQUES DANS LE DOMAINE CARDIOVASCULAIRE DE DÉRIVÉS DE QUINAZOLINEDIONE
  申请人：SANOFI

  公开号：EP2416777B1

  公开（公告）日：2014-11-12
• COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS
  申请人：Mironid Limited

  公开号：EP3774780A1

  公开（公告）日：2021-02-17
• Compounds and Their Use as PDE4 Activators
  申请人：Mironid Limited

  公开号：US20210032231A1

  公开（公告）日：2021-02-04

  The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP).
• [EN] DIARYL PIPERIDINES AS CB1 MODULATORS<br/>[FR] UTILISATION DE DIARYLE PIPÉRIDINES COMME MODULATEURS DE CB1
  申请人：SCHERING CORP

  公开号：WO2007084319A2

  公开（公告）日：2007-07-26

  [EN] A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.
  [FR] L'invention concerne des composés de formule (I), ou un sel de qualité pharmaceutique, un solvate, ou un ester de ceux-ci, utilisés dans le traitement des maladies, des troubles ou des états pathologiques tels que le syndrome métabolique (par exemple, l'obésité, le tour de taille, le profil lipidique et la sensibilité à l'insuline), les troubles neuroinflammatoires, les troubles cognitifs, la psychose, le comportement de dépendance, les troubles gastrointestinaux ainsi que les affections cardiovasculaires.
• [EN] COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'ACTIVATEURS DE PDE4
  申请人：MIRONID LTD

  公开号：WO2019193342A1

  公开（公告）日：2019-10-10

  The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3',5-adenosine monophosphate (cAMP).